BIAF
bioAffinity Technologies, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$15.27
+19.48%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$9.04M
MomentumView details →
1D Return
+19.48%
YTD Return
+5.42%
RSI (14)
81.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$9.04M
RSI (14)
81.9
MomentumView details →
1D Return
+19.48%
YTD Return
+5.42%
SummaryUpdated Jun 1, 2026
bioAffinity Technologies, Inc. (NASDAQ:BIAF) is a biotechnology company founded in 2014 and based in San Antonio, Texas. The company went public in September 2022 and specializes in developing non-invasive diagnostic tests and targeted cancer therapeutics. bioAffinity Technologies operates in the medical diagnostics and research sector, focusing primarily on early detection of lung cancer through innovative testing methods and researching targeted therapies to treat cancer at the cellular level.
Similar companies
Latest newsMore news →
bioAffinity Technologies and AvMEDICAL announced a nationwide federal healthcare distribution agreement for CyPath Lung, expanding sales reach and access to government healthcare systems.17d agobioAffinity Technologies, Inc. completed a private placement on August 12, 2026, issuing pre-funded warrants, Series A warrants, and Series B warrants, raising approximately $4 million in gross proceeds.22d agobioAffinity Technologies reported its financial results for the second quarter of 2026.28d ago